PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the most common human malignancies worldwide with very poor prognosis. Resistance to targeted therapeutic drugs such as sorafenib remains one of the major challenges in clinical treatment. In the present study, PARP1 was found to be highly expressed in human...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mol Cancer
Hlavní autoři: Yang, Xiao-Dong, Kong, Fan-En, Qi, Ling, Lin, Jia-Xin, Yan, Qian, Loong, Jane Ho Chun, Xi, Shao-Yan, Zhao, Yue, Zhang, Yan, Yuan, Yun-Fei, Ma, Ning-Fang, Ma, Stephanie, Guan, Xin-Yuan, Liu, Ming
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2021
Témata:
Letter to the Editor
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7824946/
https://ncbi.nlm.nih.gov/pubmed/33485358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-021-01315-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky